Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA
however remains insufficiently understood. A better understanding of the mechanisms
underlying the clinical effects of tralokinumab would be of great clinical benefit since it
may ultimately help us to identify more precisely candidate patients who may benefit from a
therapy with tralokinumab.